



Regeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference

February 25, 2010

TARRYTOWN, N.Y., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Building a Proprietary and Partnered Pipeline of Antibodies" at the RBC Capital Markets Healthcare Conference on Wednesday, March 3, 2010. The panel discussion will be broadcast live at 2:05 p.m. Eastern Time and may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through April 2, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com

Contact Information:

Peter Dworkin	Laura Lindsay
Investor Relations	Media Relations
914.345.7640	914.345.7800
peter.dworkin@regeneron.com	laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved